Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors

Study Title
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors
Teva Identifier
TV56278-ONC-10203
ClinicalTrials.gov Identifier
NCT06480552
Study Status
Recruiting
Trial Condition(s)
Advanced Solid Tumors
Interventions
Drug: TEV-56278

Study Description

The primary objectives of this trial are to: -Characterize the safety and tolerability of TEV-56278 -Determine the Recommended Phase 2 Dose (RP2D) -Evaluate antitumor activity of TEV-56278 -Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab -Determine a RP2D of TEV-56278 in combination with pembrolizumab
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 64 Years
Trial Duration
July 22, 2024 - February 25, 2031
Phase
Phase 1

Study Type

Interventional